-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2025-521711-39-00
5
2026-05-17
Lewy body Dementia psychosis (LBDP)
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-521730-28-00
4
2026-03-30
Colorectal Cancer with Cancer Cachexia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2025-520623-24-00
7
2025-11-19
MTAP-deleted Solid Tumors
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2023-508057-19-00
5
2025-09-23
Advanced HER2-expressing Biliary Tract Cancer
-
2025-521305-40-00
1
2025-07-22
Participants with Advanced Solid Tumors
-
2024-511166-36-00
5
2025-06-13
Moderate to Severe Plaque Psoriasis
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2023-508015-23-00
5
2025-04-11
Ovarian cancer recurrent
-
2024-512659-19-00
10
2025-03-31
Advanced Melanoma
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy
-
2024-512926-27-00
5
2024-12-12
patients with estrogen receptor-positive/human epidermal growth factor
-
2024-512707-40-00
4
2024-11-07
RELAPSING MULTIPLE SCLEROSIS
-
2023-504358-36-00
5
2024-10-17
multiple sclerosis
-
2024-511404-17-00
5
2024-10-07
Unresectable or metastatic NRAS mutant cutaneous melanoma
-
2023-504231-41-01
10
2024-10-02
Locally advanced or metastatic urothelial cancer